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Background: Acute lymphoblastic leukemia (ALL) is the most worldwide common type of childhood cancer. Methylenetetrahydro-
folate reductase (MTHFR) and 5-methyltetrahydrofolate-homocysteine methyltransferase (MTR) participate in folate pathways 
and are known as critical factors for DNA integrity as well as DNA hypomethylation. The aim of this work is to investigate fre-
quency of MTHFR (677C→T and 1298A→C) and MTR (2756A→G) polymorphisms and their interaction with respect to possible 
effect on risk of childhood ALL among North Indian population. Procedure: A case control study from has been conducted on bone 
marrow and peripheral blood samples from 125 ALL patients and 100 sex-age matched healthy controls using PCR-RFLP 
method. Results: No statistically significant differences were observed for different genotypes between patients and controls (p>0.05). 
Significant difference for the risk of ALL in individuals having genotype of MTHFR 677TT (OR=0.61, 95% CI=0.21–1.77) and 
MTHFR 1298CC (OR=0.56, 95% CI=0.18–1.68) was not observed. The correlation of SNP of MTR gene and risk of ALL was 
not observed, too. Conclusions: The differences in distribution of possible combined genotypes of MTHFR (677C→T, 1298A→C) 
and MTR (2756A→G) between ALL patients and controls were statistically insignificant.
Key Words: methylenetetrahydrofolate reductase; 5-methyltetrahydrofolate-homocysteine methyltransferase; acute lymphoblastic 
leukemia; hypomethylation.
Acute lymp�oblastic leukemia �ALL� is a malignant 
neoplasm of �ematopoietic stem cells� w�ic� is t�e 
most common cancer among c�ildren wit� a peak 
incidence in ��5 years of age [�]. It accounts for ��% 
of c�ild�ood cancers �c�ildren younger t�an �5 years� 
[�]. It is still t�e most common malignant disorder 
in c�ild�ood and principal cause of deat� due to disease 
in t�e pediatric age group� especially prevalent in males 
[�]. Interaction of genetic and environmental factors to-
get�er may en�ance t�e risk of leukemogenesis [�� �].
Folate metabolism plays crucial role in cellular 
functioning and it serves as donor of one carbon for 
t�e synt�esis of purines and pyrimidines w�ic� are 
used for t�e synt�esis of RNA and DNA [�� 5�7]. Nor-
mal metabolism of folate mig�t be affected by imbal-
ance of nutrition� cellular transport interruption and 
mutation in folate-related genes. Several mutations 
in folate-related gene sequences �ave been reported. 
However� t�e effect of t�ese mutations on folate re-
lated genes still is unclear [�� �]. Deficiency of folate 
or non-�omogenous distribution of folate vitamins 
may influence t�e risk of cancer by misincorporation 
of uracil into DNA and leading to double-strand breaks 
and c�romosomal damage� DNA �ypomet�ylation/de-
met�ylation of some tumor suppressor genes by w�ic� 
it modulate t�e leukemogenesis [����].
T�e met�ylenetetra�ydrofolate reductase �MTHFR) 
gene is located on c�romosome �p�6 [��] and 
translated to enzyme w�ic� catalyzes t�e reduction 
of 5� ��-met�ylenetetra�ydrofolate to 5-met�yltetra-
�ydrofolate. 5-met�yltetra�ydrofolate acts as a carbon 
donor for de novo met�ionine synt�esis and DNA met�-
ylation [����5]. �THFR influences t�e process of DNA 
met�ylation and distribution of uridylates and t�ymi-
dylates bases for DNA synt�esis and repair. T�erefore 
due to its role in folate pat�ways� it makes t�e �THFR 
an important candidate for study of cancer predispos-
ing gene [��� �5��7]. Two frequently reported and 
well-studied mutations in sequence of met�ylenetetra-
�ydrofolate reductase gene are �MTHFR 677C→T and 
��9�A→C� w�ic� reduce t�e activity of encoded enzyme 
[�6� �7]. T�e folate used for synt�esis of purine and 
pyrimidine is accumulated in t�e form of 5-met�yltet-
ra�ydrofolate �t�e most abundant form in wild-type 
MTHFR 677 CC subjects� [��� �9]. 
5-met�yltetra�ydrofolate-�omocysteine met�yl-
transferase �MTR� gene is located on �q��. It is t�e 
enzyme w�ic� catalyzes t�e transfer of met�yl base from 
5-met�yl THF to �omocysteine [��]. It is reported to �ave 
a polymorp�ism in locus �756 �A→G i.e. glycine→aspartic 
acid�� resulting in reduced enzyme activity and it is con-
sidered as a prime cause for elevation of �omocysteine 
and subsequently DNA �ypomet�ylation [��� ��]�
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Several reports �ave indicated t�at substitutions 
of C→T at locus 677� A→C at locus ��9� of MTHFR 
gene and A→G at locus �567 of �TR gene reduce t�e 
enzyme activity and result in �ypomet�ylation of DNA 
and subsequently reduced incidence of DNA double-
strand breakage [��]. Hence� t�e study of t�ese SNPs 
can rationally assist to determine t�e risk of group 
to ALL and also can be used for study of development 
and progression of c�ild�ood ALL in t�e population 
study. T�e aim of t�is work is to investigate frequency 
of �THFR and �TR polymorp�isms and t�eir interac-
tion wit� respect to possible effect on risk of c�ild�ood 
ALL among Nort� Indian population.
METHODS
Specimens. Total ��5 bone marrow aspirates were 
collected from t�e patients at initial time of diagnosis 
and prior to any treatment during admission to He-
mato-oncology ward ����7����9�� Advanced Pedi-
atric Center� PGI�ER� C�andigar�� India. Informed 
consent was obtained from all patients in accordance 
wit� t�e institutional guidelines and t�e declaration 
of PGI�ER. T�e et�ical committees of PGI�ER ap-
proved t�e protocol. 
Diagnosis was based on morp�ological� cytogenetic 
and immunop�enotypic criteria of WHO classification 
[�9] by Department of Hematology� PGI�ER. T�e clinical 
c�aracteristic of t�e ALL patients are s�own in Table �.
Table 1. Demography of study
Variable Patients Controls
Gender
Male 97 (77.6%) 77 (77%)
Female 28 (22.4%) 23 (23%)
Age 
Mean (±SD) 6.46 (±3.34) 6.55 (±3.37)
Range 1—14
Age group
<2 years 12 (9.6%) 11 (11%)
2–5 years 43 (34.4%) 33 (33%)
>5 years 70 (56%) 56 (56%)
NCI Risk group
Standard 103 (82.4%) -
High 22 (17.6%) -
Control samples �n=���� were obtained from blood 
of �ealt�y donors wit� respect of median and mean 
of age and sex of patients. T�e mononuclear cell frac-
tion was separated from bone marrow aspirate and 
blood by Ficoll density gradient centrifugation �Ficoll 
Hystopaqu� Sigma Aldric�� USA� and was used for DNA 
isolation. All samples contained at least ��% blast cells. 
DNA isolation. DNA was extracted from mono-
nuclear cells of bone marrow and blood by standard 
proteinase K digestion followed by p�enol-c�loroform 
met�od [�7]. DNA quantity and quality was determined 
by spectrop�otometry via measuring t�e optical den-
sity at �6� nm and ��� nm of t�e prepared diluted DNA 
�� OD at �6� nm unit =5� µg/mL� and �6� nm/��� nm.
Detection of MTHFR 677C→T, 1298A→C and 
MTR 2756 A→G SNPs. Genomic DNA containing t�e 
polymorp�ic sites was amplified by polymerase c�ain 
reaction �PCR� wit� specific primers for eac� gene 
�Table �� using �5 ng genomic DNA� �.5 µ� of eac� 
of t�e primers� ��� µ� deoxyribonucleotide trip�os-
p�ates �dNTPs�� �� m� Tris �tris-��ydroxymet�yl� ami-
nomet�ane��HCl �pH �.��� �.5 m� �gCl�� 5� m� KCl� 
and �.5 units of Taq polymerase �Sigma�Aldric�� USA� 
in a total volume of 5� µl.
T�e PCR conditions were as mentioned in Table �. 
RFLP was performed wit� restriction enzymes accord-
ing to t�e manufacturer’s instructions ��BI� Fermentas� 
Burlington� ON� Canada�. T�e restriction digestion was 
visualized after electrop�oresis on �.5% agarose gel. 
T�e amplified PCR product of �THFR 677C→T, digested 
by HinfI restriction enzyme. T�ose patients carrying 
genotype CC s�owed a single band of �9� bp� w�ereas 
carrier of genotype TT s�owed bands of �75 and �� bp� 
and t�ree bands of �9�� �75 and ��bp appeared wit� 
genotype CT. After digesting wit� MboII for detect-
ing �THFR ��9�A→C, t�e bands 56� ��� ��� �� and 
�� bp were observed for genotype AA� w�ereas� t�e 
expected bands for genotype CC were ��� ��� �� and 
�� bp and for �eterozygous �AC�� t�e size of expected 
bands were ��� 56� ��� ��� �� and �� bp. T�e amplified 
product of �TR �756A→G gene followed by digestion 
by HaeIII� t�e carrier of genotype AA s�owed t�e single 
band at ��� bp. T�ose �omozygous for mutation �GG� 
s�owed bands of ��� and ��bp. Heterozygous �AG� 
represented bands of ���� ��� and �� bp.
Table 2. Primer sequences and PCR Conditions
Gene Primer Sequence (5’- 3’) Annealing temp. (°C) / time / cycle
MTHFR 677
F TGA AGG AGA AGG TGT CTG CGG GA 59 / 1 min / 35
R AGG ACG GTG CGG TGA GAG TG
MTHFR1298
F CTT TGG GGA GCT GAA GGA CTA CTA C 59 / 1 min / 35
R CAC TTT GTG ACC ATT CCG GTT TG
MTR2756
F TGT TCC AGA CAG TTA GAT GAA AAT C 60 / 1 min / 35
R GAT CCA AAG CCT TTT ACA CTC CTC  
Statistical analysis. Distribution of MTHFR 
677C→T and MTHFR 1298A→C and MTR 2756A→G va-
riants among patients and controls were tabulated for 
cases and controls �Table ��. Wit� respect to assump-
tion w�ic� indicates t�at MTHFR and MTR genotypes 
may be associated wit� t�e risk of ALL� we tested 
genotypes interaction in models for acute lymp�oblastic 
leukemia and t�e interaction of t�ese genes wit� age� 
sex and �ematological classification� risk group. T�e 
χ� test was used to examine differences in frequencies 
between MTHFR 677C→T, MTHFR 1298A→C and MTR 
2756A→G genotypes in cases and controls. Fis�er exact 
test was used w�en cell numbers were less t�an 5. T�e 
relations�ip between MTHFR and MTR genotypes and 
risk of ALL was assessed by means of t�e odds ratio �OR� 
wit� 95% confidence interval �95%CI�. It was calculated 
using bot� conditional and unconditional logistic regres-
sion �adjusting for age and sex� by use of software version 
��.5 �SPSSs� C�icago� IC�� and EPI software version �.�.
Table 3. Frequencies of MTHFR 677C→→T, 1298A→→C and MTR 
2756A→→G geno types in case and control 
Genotype Patients (n = 125)
Controls 
(n = 100) OR CI (95%) P-Value
MTHFR C677T
CC 54 (43.2%) 40 (40%) 1
CT 62 (49.6%) 49 (49%) 0.94 0.52–1.69 0.93
TT 9 (7.2%) 11 (11%) 0.61 0.21–1.77 0.30
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Genotype Patients (n = 125)
Controls 
(n = 100) OR CI (95%) P-Value
CT+TT 71 (56.8%) 60 (60%) 0.88 0.50–1.55 0.72
MTHFR A1298C
AA 52 (41.6%) 40 (40%) 1
AC 65 (52%) 49 (49%) 1.02 0.56–1.85 0.94
CC 8 (6.4%) 11 (11%) 0.56 0.18–1.68 0.37
AC+CC 73 (58.4%) 60 (60%) 0.94 0.53–1.66 0.91
MTR A2756G
AA 74 (59.2%) 58 (58%) 1
AG 44 (35.2%) 35 (35%) 0.99 0.54–1.80 0.92
GG 7 (5.6%) 7 (7%) 0.78 0.23–2.66 0.87
AG+GG 51 (40.8%) 42 (42%) 0.95 0.54–1.68 0.96
RESULTS
Demograp�ic data of cases and controls �as been 
summarized in Table �. T�e variables �ave also been 
categorized for ALL immunop�enotypes. T�e blast 
lineage� NCI risk groups of ALL patients �ave been 
tabulated in Table �. 9�.�% patients were diagnosed 
wit� B-lineage ALL and 5.6% wit� T-lineage ALL. T�e 
distribution of ALL patients on t�e basis of NCI risk 
groups were ��.�% in standard risk group and �7.6% 
in �ig� risk group.
T�e mean age �±SD� of all cases and controls 
were 6.�6 �±�.��� and 6.55 �±�.�7� years �p=�.��5� 
respectively. Around 9.6% of patients were in t�e 
age-group of age ≤� years and ��.�% were in t�e age-
group of �< age ≤ 5 and 56% were in age of more t�an 
5 years� w�ereas it was ��� �� and 56% respectively 
for �ealt�y controls. T�e number of males and females 
among cases and controls were almost similar �77.6: 
77 for males and ��.�: �� for females� respectively�. 
T�e distribution pattern of ALL patients and controls 
according to place of living were divided in to two 
groups �a� urban �b� rural. �5.�% of patients were 
living in urban and 6�.�% were living in rural areas. 
T�e values for controls were not different from cases 
���% urban and 6�% rural�. T�e distribution of ALL 
cases and controls among different states of Nort� 
India s�owed t�e most of t�e patients in present study 
were from Punjab ���%�� followed by Haryana ��7.�%�� 
Uttar Prades� ���.�%�� Himac�al Prades� ��%�� C�an-
digar� ��.�%� and J&K ��%�. Similar distribution was 
seen among t�e controls.
T�e prevalence of genotypes of �THFR and 
�TR genes in patients and controls were depicted 
in Table �. T�ere is no significant differences between 
patients and controls in t�is study population.T�e fre-
quencies of �THFR C677T/A� �THFR A��9�C� �TR 
A�756G variants in c�ild�ood ALL and �ealt�y controls 
did not deviate significantly from t�e Hardy — Weinberg 
equilibrium. Interestingly� all genotypes of �THFR 
677TT� �THFR ��9�CC and �TR �756GG s�ow slig�t 
decreasing of t�e risk disease� but no significant dif-
ference �p>�.�5� was observed between patients and 
controls in all t�ese studied genes.
T�e frequencies of MTHFR 677C→T, MTHFR 
1298A→C and MTR 2756A→G in stratified risk group 
is s�own in Table �. Significant difference of distribu-
tion of genotypes between standard and �ig� risk 
group was not observed.
Table 4. Frequencies of genotypes in standard and high risk group patients
Genotype
Standard 
Risk Group
103 (%)
High Risk 
Group
22 (%)
OR CI (95%) P-Value
MTHFR C677T
CC 45 (43.7) 11 (50) Ref. - -
CT 51 (49.5) 9 (40.9) 1.39 0.48–4.05 0.67
TT 7 (6.7) 2 (9) 0.97 0.67–1.04 1
CT+TT 58 (56.3) 11 (50) 1.29 0.47–3.65 0.76
MTHFR A1298C
AA 43 (41.7) 9 (41) Ref. - -
AC 53 (51.4) 11 (50) 1.01 0.34–2.93 0.81
CC 7 (6.7) 1 (4.5) 1.06 0.79–1.41 1
AC+CC 60 (58.2) 12 (54.5) 1.05 0.37–2.97 0.88
MTR A2756G
AA 60 (58.2) 14 (63.6) Ref. - -
AG 38 (36.9) 7 (31.8) 1.27 0.43–3.85 0.82
GG 5 (4.8) 1 (4.5) 1.03 0.71–1.49 1
AG+GG 43 (41.7) 8 (36.3) 1.25 0.44–3.62 0.82
T�e comparison of t�e frequency distribution 
of MTHFR 677C→T, MTHFR 1298A→C and MTR 
2756A→G polymorp�isms between case and con-
trol on t�e bases of sex s�owed t�at t�e distribution 
of �THFR 677 and �THFR ��9� and �TR�756 variants 
among t�e bot� sex were not significantly different 
�p>�.�5�. Also on t�e basis of age-group �t�e age 
of t�e c�ildren at t�e time of diagnosis�� distribution 
of genotypes of MTHFR 677C→T, MTHFR 1298A→C and 
MTR 2756A→G were calculated. However� no signifi-
cant difference was detected �Table 5�.
T�e effect of gene-gene interaction between 
�THFR polymorp�isms on susceptibility of c�ild�ood 
ALL was investigated furt�er; significant association 
between t�e interaction of �THFR variants and de-
Table 5. Frequencies of genotypes in different age groups
Age <2 2 < Age < 5 Age > 5
Genotype
Patients
(n=12) 
(%)
Controls
(n=11) 
(%)
OR CI (95%) P-Val-ue
Patients
(n=45)
(%)
Controls
(n=32)
(%)
OR CI (95%) P-Va-lue
Patient
68 (%)
Control
57 (%) OR CI (95%)
P-Va-
lue
MTHFR C677T
CC 6 (50) 4 (36.3) - - - 19 (42.2) 14 (43.7) - - - 29 (42.6) 22 (38.5) - - -
CT 5 (41.6) 6 (54.5) 0.76 0.33–1.72 0.6 23 (51.1) 16 (50) 1.06 0.37–1.52 0.9 34 (50) 25 (43.8) 1.03 0.45–2.36 0.91
TT 1 (8.3) 1 (9) 0.83 0.19–3.64 1 3 (6.6) 4 (12.5) 0.74 0.3–1.84 0.67 5 (7.3) 7 (12.2) 0.73 0.36–1.49 0.52
CT+TT 6 (50) 7 (63.6) 0.77 0.34–1.67 0.68 26 (57.7) 20 (62.5) 0.96 0.35–2.6 0.89 39 (57.3) 32 (56.1) 0.95 0.43–2.11 0.95
MTHFR A1298C
AA 5 (41.6) 4 (36.3) - - - 17 (37.7) 12 (37.5) - - - 30 (44.1) 24 (42.1) - - -
AC 7 (58.3) 5 (45.4) 1.05 0.49–2.23 1 24 (53.3) 17 (53.1) 1 0.34–2.29 0.81 34 (50) 27 (47.3) 1.01 0.45–2.25 0.86
CC 1 (8.3) 1 (9) 0.90 0.20–4.05 1 3 (6.6) 3 (9.3) 0.85 0.36–2.01 1 4 (5.8) 7 (12.2) 0.65 0.29–1.48 0.40
AC+CC 8 (66.6) 6 (54.5) 1.03 0.49–2.16 1 27 (60) 20 (62.5) 0.95 0.34–2.70 0.88 38 (55.8) 34 (59.6) 0.89 0.41–1.93 0.89
MTR A2756G
AA 7 (58.3) 6 (54.5) - - - 28 (62.2) 20 (62.5) - - - 39 (57.3) 32 (56.1) - - -
AG 4 (33.3) 4 (36.3) 0.93 0.39–2.19 1 16 (35.5) 11 (34.3) 1.04 0.36–3.02 0.86 24 (35.2) 19 (33.3) 1.02 0.72–1.43 0.91
GG 0 (0) 0 (0) - - - 2 (4.4) 2 (6.2) 0.86 0.31–2.35 1 5 (7.3) 5 (8.7) 0.91 0.47–1.75 1
AG+GG 4 (33.3) 4 (36.3) 0.93 0.39–2.19 1 18 (40) 13 (40.6) 1 0.68–1.46 0.83 29 (42.6) 24 (42.1) 0.99 0.46–2.16 0.87
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velopment and progression of ALL among t�e c�ildren 
in t�e present study was on observed �Table 6�.
As it is s�own in Table �� individuals w�o carried t�e 
genotype of �THFR 677TT� did not s�ow and differ-
ence on risk of ALL �OR=�.6�; 95% CI=�.����.77�. T�e 
adjusted OR for carriers of �THFR ��9�CC genotype 
was calculated. It was �.56 �95% CI=�.����.6�� w�ic� 
statistically did not s�ow significance reduction on sus-
ceptibility against of c�ild�ood ALL. �oreover� t�is 
trace was not observed for variants of 2756A→G gene. 
T�e significance was not altered w�en t�ese � poly-
morp�isms were evaluated in combination �Table 7�. 
Table 6. Interaction of MTHFR genotypes between case and control 
Combined geno-
types
Patients
(n = 125)
Controls
(n = 100) OR CI (95%) P-Value
677CC/1298AA 22(17.6%) 16 (16%) - - -
677CT/1298AA 40 (32%) 20 (20%) 0.52 0.1–1.54 0.18
677TT/1298AA 8 (17.6%) 12 (12%) 1.35 0.34–5.47 0.63
677CC/1298AC 20 (6.4%) 22 (22%) 0.51 0.17–1.48 0.16
677CT/1298AC 17(13.6%) 18 (18%) 0.49 0.16–1.5 0.16
677TT/1298AC 0 (0%) 0 (0%) NA NA NA
677CC/1298CC 13(10.4%) 12 (12%) 0.73 0.2–2.55 0.57
677CT/1298CC 5 (4%) 7 (7%) 0.72 0.35–1.48 0.51
677TT/1298CC 0 (0%) 0 (0%) NA NA NA
Table 7. Frequencies of combined genotype in childhood ALL and control. 
Genotype is in respect of MTHFR 77C→→T,1298A→→C and MTR 2756A→→G 
Combined geno-
types
Patients
(n = 125)
Controls
(n = 100) OR CI (95%) P-Value
CCAAAA 14 7 Ref. - -
CCAAAG 6 5 0.82 0.44–1.52 0.70
CCAAGG 5 4 0.83 0.43–1.61 0.68
CCACAA 15 8 0.98 0.64–1.50 0.82
CCACAG 12 7 0.86 0.19–3.81 0.92
CCACGG 0 0 NA NA NA
CCCCAA 2 2 0.75 0.27–2.09 0.60
CCCCAG 2 1 1 0.43–2.35 1
CTAAAA 18 9 1 0.25–3.97 1
CTAAAG 8 1 1.33 0.91–1.95 0.37
CTAAGG 2 1 1 0.43–2.35 1
CTACAA 15 10 1.33 0.34–5.32 0.64
CTACAG 13 5 0.77 0.16–3.71 0.7
TTAAAA 1 1
DISCUSSION 
Polymorp�ism of genes w�ic� regulate t�e me-
tabolism of folate is t�e important p�enomenon w�ic� 
may play role in cancer susceptibility by decreasing 
folate status or by interference in distribution of folate 
in cells could influence t�e risk of ALL [��]. C�ild�ood 
ALL is more prone to environmental exposures dur-
ing fetal and infant stage [��]. Reduction in t�e level 
of 5� ��-met�ylene�THF ��THFR substrate�� w�ic� 
is essential for synt�esis of t�ymidylate� could lead 
to uracil misincorporation into DNA [��] and furt�er 
diminis�ed t�e DNA repair system and increased t�e 
susceptibility to double-strand breakage t�ere by lead-
ing to t�e c�romosomal damage and translocation 
[����7]. Folate availability is critical for DNA integrity� 
required for t�e transfer of met�yl groups in t�e bio-
synt�esis of t�ymidilate. In t�is study we tried to find 
out w�et�er �THFR variants and �TR polymorp�ism 
play a protective role in a c�ild�ood ALL.
T�e decrease in activity of �THFR could affect t�e 
nucleotide synt�esis by increasing availability of t�e 
5� ��-met�ylene�THF w�ic� is required for DNA syn-
t�esis and cell division. Folate distribution decreases 
t�e transmet�ylation capacity and t�ereby decreasing 
S-adenosylmet�ionine / S-adenosyl�omocysteine 
ratio and met�ylation of �omocysteine to met�ionine. 
Diminis�ed folate availability increases t�e probability 
of mis-incorporation of uracil in DNA strand at t�e 
time of replication and subsequently increasing t�e 
frequency of c�romosomal breakage in �uman leu-
kocyte [�����].
A �ematological malignancy like ALL is more vulner-
able to DNA and c�romosomal damage because folate 
deficiency in t�em cannot accomplis� t�e demand 
of �asty DNA synt�esis in uncontrolled and rapidly 
proliferating �ematopoitic cells. DNA �ypomet�ylation 
and uracil misincorporation are considered important 
factors in carcinogenesis [��� ��].
Several groups �ave reported t�at t�e polymor-
p�isms w�ic� reduce t�e �THFR activity were associ-
ated wit� t�e reduced risk of leukemia and lymp�oma 
[��� ��� ��]. ALL patients wit� polymorp�isms in serine 
�ydroxymet�yl transferase gene and t�ymidylate 
synt�ase genes are considered as low risk group 
[�5� �5]. ALL cases wit� a polymorp�isms in �TR 
�756A→G genotype� s�owed reduction by 5.6-fold 
in adult ALL risk [�5]. Not only �TR �756A→G vari-
ants were considered as a risk allele for ALL but also 
in combination wit� t�e �THFR variants [��]. 
In t�is study� attempts were made to evaluate t�e 
associations between t�e �THFR 677C→T� �THFR 
1298A→C and �TR �756A→G polymorp�isms and 
t�e risk of ALL in t�e ��5 cases of t�e c�ild�ood ALL 
in nort� India compared wit� t�e sex and age matc�ed 
controls. It �as been reported t�at bot� �THFR poly-
morp�isms reduce t�e susceptibility to adult and 
c�ild�ood lymp�oid leukemia �owever not in myeloid 
leukemia [��� ��� �6���]. 
T�e significant protective effect of MTHFR 
677C→T variant but not �THFR ��9�A→C in t�e Brazil-
ian population to decrease t�e risk of c�ild�ood ALL 
�as been reported by de Franc�is et al. [��]. Recently� 
Sood et al. [��] demonstrated t�e significant protec-
tive effect of MTHFR 677C→T variant but not �THFR 
��9�A→C in t�e nort� Indian population to decrease 
t�e risk of c�ild�ood ALL. Wiemels et al. [��] reported 
t�e protective effect of �THFR 677C→T polymorp�ism 
on t�e risk for infant leukemia in t�e UK population but 
not for �THFR 1298A→C polymorp�ism; also it was 
demonstrated t�at 677C/T frequency was �ig�er in ALL 
patients wit� �LL rearrangements� low in ALL wit� 
�yper-diploidy indicating t�at impact of 677C/T vari-
ant on development and progression of leukemia 
mig�t vary between different subtype of ALL [�7]. 
�atsuo et al. [��] provided t�e evidence w�ic� �THFR 
mutant alleles are associated wit� lower susceptibil-
ity to ALL. Some ot�er studies also reconfirmed t�at 
bot� �THFR polymorp�isms decreased t�e risk for 
c�ild�ood ALL in Frenc��Canadian population [5]. 
T�e recent report by Reddy et al. [�9] suggested 
a possible protective effect of �THFR �677C→T� and 
�THFR ��9�A→C� for t�e first time t�ey reported 
gender-bias protective effect of 677CT /��9�AA and 
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677CT/��9�AC toward of female ALL patients. Yeo� 
et al. [��] ���� demonstrated association between 
�THFR 1298A→C and increasing t�e risk of ALL among 
male patients.
However� ot�er researc� groups reported no as-
sociation between �THFR polymorp�isms and t�e risk 
for c�ild�ood ALL� from different et�nic groups [��� 
�5� ��]. Wang et al. [��] in t�eir recent meta-analysis 
reported albeit �THFR C677T was found previously 
to be associated wit� increased risks of colorectal 
cancer� leukemia� and gastric cancer� but on t�e bases 
of t�is meta�analysis� t�ey could not find evidence 
for a main role of �THFR C677T in t�e leukemogesis 
of c�ild�ood acute lymp�oblastic leukemia.
In t�e present study� significant difference between 
patients and �ealt�y controls was not found� but also 
our result did not s�ow t�e significant reduction in t�e 
risk of ALL and increasing t�e tolerance induced 
by T and C alleles in position of 677 and ��9� of �THFR 
gene� respectively� in ALL patients in nort� Indian 
population.
We tried to analyze t�e influence of eac� polymor-
p�ism of �THFR and �TR individually and in com-
bination and t�eir effect on t�e risk for c�ild�ood 
ALL. We could not observe significant associations 
between t�e genetic polymorp�isms of t�e folate me-
tabolizing enzymes and �TR on t�e risk for c�ild�ood 
ALL in our population of study.
However� t�e contradictory results were observed 
in association of genetic polymorp�isms in t�e folate 
metabolic pat�way wit� t�e risk for adult ALL [��� �5� 
�6� ��� ��]. Also� Gemmati et al. [�6] and Lincz et al. 
[��] observed t�at MTR 2756A→G polymorp�ism re-
duced t�e risk for adult ALL and lymp�oma. On t�e 
ot�er �and� Skibola et al. [�5] and �atsuo et al. [��] 
reported on increased risk for different types of adult 
lymp�oma in carriers for at least one G allele in locus 
�756 of �TR gene. No association �as been observed 
between �TR �756A→G polymorp�ism and t�e risk for 
adult ALL according to [�5� ��]. Our work also s�owed 
no association between �TR �756A→G polymorp�ism 
and t�e risk of c�ild�ood ALL. T�e inconsistencies 
of results mig�t be attributed to some variables in study 
of population like size of sampling� age and nutritional 
folic acid in diet. Rosenberg et al. [��] s�owed t�at 
t�e adequate folic acid consumption in a popula-
tion may increase t�e frequency of t�e �THFR 677T 
allele� in contrast insufficient level of folate in diet 
may results in decreasing t�e T allele frequency. T�is 
can justify t�e different frequency of �THFR allele 
in population of t�is study as compared wit� Reddy 
et al. [�9] may be influenced by different level of folic 
acid in diet of different et�nic groups in India. T�us 
t�e polymorp�ism of t�ese genes did not s�ow any 
effect on ALL susceptibility� so it could be interpreted 
t�at ot�er molecular mec�anisms like �ypermet�yl-
ation mediated gene silencing may play an important 
role in etiology of ALL in nort� Indian population. T�e 
mec�anism proposed to explain t�ese associations 
was t�e s�unt of folate metabolism versus t�ymidine 
and purine synt�esis� w�ic� could reduce t�e possibil-
ity of t�e incorporation of uracil into DNA and protect 
against carcinogenesis. It �as been proposed t�at 
s�unt of folate metabolism encounters t�e synt�esis 
of t�ymidine and purine� reduces misincorpration 
of uracil into DNA and protect from any damage w�ic� 
lead to arising cancer [��� �9].
In conclusion� t�e present study provided t�e evi-
dence t�at �THFR (677 C→T), �THFR �1298 A→C) and 
�TR (2576A→C) are not associated wit� decreased 
risk of c�ild�ood ALL and did not s�ow significant 
effect on progression and development of c�ild-
�ood ALL. In t�e ot�er words� we found t�at �THFR 
677C→T and 1298A→C may could not be considered 
as a crucial and probable marker for ALL develop-
ment and progression and also could not be used for 
treatment strategies for c�ild�ood ALL� as epigene-
tic mec�anisms are more important in progression 
of c�ild�ood ALL. T�e larger studies� w�ic� in turn will 
be able to provide support to truly significant finding 
t�roug� muc� larger combined and comparative data 
sets� are necessary in t�is regard.
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